<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551394</url>
  </required_header>
  <id_info>
    <org_study_id>2011-001515-31</org_study_id>
    <nct_id>NCT01551394</nct_id>
  </id_info>
  <brief_title>Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis</brief_title>
  <acronym>NeoMero-1</acronym>
  <official_title>Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Clinical or Confirmed Late-onset Sepsis : a European Multicenter Randomised Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PENTA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III multicentric international randomized trial is designed to compare the&#xD;
      efficacy of Meropenem to the standard of care in infants below 90 days of age with clinical&#xD;
      or confirmed late-onset sepsis (LOS).&#xD;
&#xD;
      The aim is to assess efficacy , pharmacokinetics and safety of Meropenem which are not well&#xD;
      known and documented in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal objective is to compare the efficacy at test of cure (TOC) visit of meropenem&#xD;
      to the standard of care (SOC) in the treatment of clinical or confirmed LOS in infants ≤ 90&#xD;
      days of postnatal age.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To compare the safety profile of meropenem to SOC&#xD;
&#xD;
        -  To compare the efficacy at TOC visit of meropenem to SOC in confirmed sepsis&#xD;
&#xD;
        -  To compare the response to meropenem and SOC on day 3 of antibacterial therapy&#xD;
&#xD;
        -  To compare the efficacy at TOC visit of meropenem to SOC ignoring the change of&#xD;
           antibiotic(s) for safety reasons&#xD;
&#xD;
        -  To compare the efficacy at TOC visit of meropenem to SOC by SOC regimen&#xD;
&#xD;
        -  To compare survival at follow up (FU) visit (28 day visit) in the meropenem arm and SOC&#xD;
           arm&#xD;
&#xD;
        -  To compare new infections and relapses that occur between TOC and FU visits in&#xD;
           participants with a favourable outcome at TOC visit by treatment arm&#xD;
&#xD;
        -  To define the organisms causing LOS&#xD;
&#xD;
        -  To study antibacterial susceptibility of LOS-causing organisms and to describe clinical&#xD;
           and microbiological responses according to this&#xD;
&#xD;
        -  To compare gut colonization by antibiotic resistant organisms after treatment with&#xD;
           meropenem or SOC&#xD;
&#xD;
        -  To compare bacterial eradication by treatment arm&#xD;
&#xD;
        -  To compare time to NICU discharge across the 2 arms&#xD;
&#xD;
        -  To describe PK of meropenem in infants ≤ 90 days of postnatal age with LOS&#xD;
&#xD;
        -  To evaluate genetic parameters that may affect response to therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with a favorable outcome in the two arms</measure>
    <time_frame>an expected average of 14 days</time_frame>
    <description>The proportions of participants with a favourable outcome will be calculated in the meropenem arm and in the SOC arm. A favourable outcome is met when an infant:&#xD;
Is alive&#xD;
Has resolution or significant improvement of all abnormalities that defined LOS at entry and has no new clinical or laboratory abnormalities requiring a new course of antibiotic therapy&#xD;
Has microbiological eradication either confirmed or presumed and no new pathogens identified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nature, frequency and numbers of clinical and biological adverse events</measure>
    <time_frame>3 - 28 days</time_frame>
    <description>Adverse events will also be summarised according to the need of a specific medical intervention or not. Analyses by time period will also be shown (from D0 to TOC visit and from TOC visit to follow-up). The number of patients experiencing at least one adverse event between D0 and TOC visit will be compared by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: &lt; 32 weeks GA and &lt; 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.&#xD;
Treatment duration is 11 ± 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The two accepted therapeutic options are:&#xD;
ampicillin + gentamicin (SOC regimen 1) and&#xD;
cefotaxime + gentamicin (SOC regimen 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>20 mg/kg every 8 hours (every 12 hours in the youngest age group: &lt; 32 weeks GA and &lt; 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.</description>
    <arm_group_label>Meropenem</arm_group_label>
    <other_name>Meropenem trihydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin + gentamicin or cefotaxime + gentamicin</intervention_name>
    <description>Ampicillin:&#xD;
Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours&#xD;
Gentamicin:&#xD;
Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)&#xD;
Cefotaxime:&#xD;
Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days.</description>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Ampicillin sodium</other_name>
    <other_name>Gentamicin sulphate</other_name>
    <other_name>Cefotaxime sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent form signed by the parents/carers&#xD;
&#xD;
          -  Chronological age below 90 days inclusive&#xD;
&#xD;
          -  Chronological age greater or equal to 72 hours of life at beginning of LOS&#xD;
&#xD;
          -  Clinical or confirmed sepsis&#xD;
&#xD;
               -  For infants below 44 weeks inclusive of corrected age&#xD;
&#xD;
        clinical sepsis is defined, according to the Expert Meeting on Neonatal and Paediatric&#xD;
        Sepsis (Report on the Expert Meeting on Neonatal and Paediatric Sepsis - 8 June 2010, EMA&#xD;
        London), as the presence in the last 24 hours of at least&#xD;
&#xD;
          -  two clinical criteria:&#xD;
&#xD;
               -  hyper- or hypothermia or temperature instability,&#xD;
&#xD;
               -  reduced urinary output or hypotension or mottled skin or impaired peripheral&#xD;
                  perfusion&#xD;
&#xD;
               -  apnea or increased oxygen requirement or increased requirement for ventilatory&#xD;
                  support,&#xD;
&#xD;
               -  bradycardia spells or tachycardia or rhythm instability,&#xD;
&#xD;
               -  feeding intolerance or abdominal distension,&#xD;
&#xD;
               -  lethargy or hypotonia or irritability,&#xD;
&#xD;
               -  skin and subcutaneous lesions such as petechial rash or sclerema,&#xD;
&#xD;
          -  and two laboratory criteria:&#xD;
&#xD;
               -  white blood cells (WBC) count &lt; 4 or &gt; 20 x 109 cells/L,&#xD;
&#xD;
               -  immature to total neutrophil ratio (I/T) &gt; 0.2,&#xD;
&#xD;
               -  platelet count &lt; 100 x 109/L,&#xD;
&#xD;
               -  C-reactive protein (CRP) &gt; 15 mg/L or procalcitonin ≥ 2 ng/mL,&#xD;
&#xD;
               -  glucose intolerance when receiving normal glucose amounts (8-15 g/kg/day) as&#xD;
                  expressed by blood glucose values &gt; 180 mg/dL or hypoglycemia (&lt; 40 mg/dL)&#xD;
                  confirmed at least two times,&#xD;
&#xD;
               -  acidosis as characterized by base excess (BE) &lt; -10 mmol/L or lactate with value&#xD;
                  above 2 mmol/L.&#xD;
&#xD;
        confirmed sepsis is defined as positive culture for pathogens in a sample from a normally&#xD;
        sterile site and at least one laboratory sign or clinical sign (from the list above)&#xD;
&#xD;
          -  For children above 44 weeks corrected age&#xD;
&#xD;
        clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005) as&#xD;
        at least two of the following criteria, one of which must be abnormal temperature or WBC&#xD;
        count:&#xD;
&#xD;
          -  Core temperature of &gt; 38.5 °C or &lt; 36 °C;&#xD;
&#xD;
          -  Tachycardia, defined as mean heart rate &gt; to the 95th percentile for age group in the&#xD;
             absence of external stimulus, chronic drugs, or painful stimuli or unexplained&#xD;
             persistent elevation over a 0.5 to 4 hour time period; or bradycardia, defined as a&#xD;
             mean heart rate &lt; to the 5th percentile for age group in the absence of external vagal&#xD;
             stimulus, beta blocker drugs, or congenital heart disease or unexplained persistent&#xD;
             depression over a 0.5 hour time period;&#xD;
&#xD;
          -  Mean respiratory rate &gt; to the 95th percentile for age group or mechanical ventilation&#xD;
             for an acute process not related to underlying neuromuscular disease or the receipt of&#xD;
             general anaesthesia;&#xD;
&#xD;
          -  Leukocyte count &lt; the 5th percentile or &gt; than the 95th percentile for age group (not&#xD;
             secondary to chemotherapy-induced leucopoenia).&#xD;
&#xD;
        confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site&#xD;
        and at least one laboratory sign or clinical sign (from the list above)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of any systemic antibiotics for more than 24 hours prior to the&#xD;
             randomisation, unless the change is driven by the lack of efficacy of the former&#xD;
             regimen;&#xD;
&#xD;
          -  Severe congenital malformations if the infant is not expected to survive for more than&#xD;
             3 months;&#xD;
&#xD;
          -  Other situations where the treating physician considers a different antibiotic regimen&#xD;
             necessary;&#xD;
&#xD;
          -  Known intolerance or contraindication to study medication;&#xD;
&#xD;
          -  Participation in any other clinical study of investigational drugs;&#xD;
&#xD;
          -  Renal failure (as defined by Akcan-Arikan et al., 2007) and requirement of&#xD;
             haemofiltration or peritoneal dialysis;&#xD;
&#xD;
          -  Confirmed sepsis with microorganisms known to be resistant to study therapies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Trafojer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Pediatrica, Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irja Lutsar</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu, Estonia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre Aboulker</last_name>
    <role>Study Chair</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ursula TRAFOJER</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.neomero.org</url>
    <description>Site dedicated to the NeoMero studies</description>
  </link>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>neonates</keyword>
  <keyword>meropenem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 7, 2017</submitted>
    <returned>August 9, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

